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ENGLISH SUMMARY 
The analgesic effect of opioids has been thoroughly investigated and has been known for millennia. 
Today opioids are used to treat both acute and chronic pain disorders. Strong opioids include 
morphine, methadone, fentanyl, oxycodone, and buprenorphine whereas codeine and tramadol are 
considered weak opioids. Unfortunately, the attractive analgesic properties of opioids are 
compromised by numerous gastrointestinal adverse effects, collectively known as opioid-induced 
bowel dysfunction (OIBD). One of the most prevalent adverse effects is constipation, which can be 
debilitating for the patients. Accordingly, constipation has been described thoroughly in the past. The 
treatment of OIBD is based on conventional alleviation of constipation, which does not account for the 
underlying pathophysiology. More detailed knowledge about the underlying pathophysiological 
mechanisms of opioid treatment on the gastrointestinal tract would therefore be beneficial to enhance 
our understanding of OIBD. Ultimately, the goal is to improve pain management through a reduction 
of adverse effects. 
The objective of this Ph.D. dissertation was to investigate these adverse effects in healthy 
volunteers with a novel approach based on both subjective and objective methods. The methods 
include 1) several validated questionnaires on gastrointestinal function, 2) assessment of segmental 
colorectal volumes using magnetic resonance imaging (MRI), 3) assessment of gut secretion with 
Ussing chambers, 4) assessment of gastrointestinal transit times with a novel ambulatory capsule 
system (3D-Transit), and 5) assessment of anal sphincter function and distensibility the functional 
lumen imaging probe (FLIP). The hypothesis was that a more nuanced and complete picture of OIBD 
as an entity could be obtained through the combination of these subjective and objective measures. 
Data was acquired from one randomised controlled trial where 25 healthy volunteers were treated 
with oxycodone or placebo in a double-blinded crossover design. The main results first and foremost 
included the successful development of a well-tolerated model of OIBD in healthy volunteers, based 
on questionnaire scores. During oxycodone treatment all subjects experienced a substantial impact 
on gut function with development of numerous OIBD symptoms (constipation, abdominal pain, 
bloating, straining, etc.) compared to placebo treatment. In paper I we compared MRI-based 
assessments of segmental colorectal volumes from the two baselines (before oxycodone and placebo 
treatment) to investigate whether the method was reproducible. The method showed low variability 
and was sensitive to assess the changes in segmental colorectal volumes that occur from defecation. 
Hence, the method was suitable for assessing changes in segmental colorectal volumes brought on 
by opioid treatment, which was investigated in paper II. Here we found that the volume for the 
caecum/ascending colon increased significantly during oxycodone treatment compared to placebo. In 
paper III we investigated whether opioid treatment alters gut secretion, using the Ussing chamber 
technique. We found that, at least for isolated mucosa from the rectosigmoid colon, no change in gut 
secretion occurred from opioid treatment. In paper IV gastrointestinal transit times were significantly 
prolonged during oxycodone treatment compared to placebo in the caecum/ascending colon and 
rectosigmoid colon. In the caecum/ascending colon the prolonged transit time induced by oxycodone 
 X 
could be the underlying explanation behind the observation from paper II that the volume increased in 
this segment as well. Lastly, preliminary analysis of anal sphincter function and distensibility exhibited 
a large degree of variability, which may have obscured any oxycodone-induced alterations and more 
advanced analysis of this data is pending. 
In conclusion, we have successfully developed an experimental model of OIBD in a controlled 
environment. The combination of the applied subjective and objective assessments enables a more 
thorough examination of the clinical manifestation and underlying pathophysiology of OIBD as a 
whole.  
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DANSK RESUME 
Opioidernes smertelindrende effekt er særdeles velbeskrevet og har været kendt i tusinder af år. 
Således bliver de i dag anvendt til både akutte og kroniske svært behandlelige smerter. Stærke 
opioider dækker blandt andre over morfin, metadon, fentantyl, oxycodon og buprenorphin, hvorimod 
lægemidler som tramadol og kodein regnes som svage opioider. Desværre bliver effektiv 
smertelindring ofte kompromitteret af en række gastrointestinale bivirkninger, der under én fælles 
betegnelse kaldes opioid-induceret mavetarm-dysfunktion (’opioid-induced bowel dysfunction’: OIBD). 
Heriblandt er forstoppelse en af de mest hyppigt forekommende bivirkninger, til stor gene for 
patienten og derfor desuden den hidtil bedst beskrevne bivirkning. Behandling af OIBD tager 
udgangspunkt i konventionel behandling af forstoppelse, hvilket ikke tager højde for den 
underliggende patofysiologi. Mere detaljeret viden om de underliggende patofysiologiske mekanismer 
på mavetarm-kanalen vil derfor være gavnligt. En øget forståelse for OIBD vil kunne bidrage til at 
reducere bivirkningerne, hvilket i sidste ende vil kunne optimere effektiv smertebehandling for den 
individuelle patient. 
Målsætningen for denne ph.d.-afhandling er, at undersøge disse bivirkninger hos raske frivillige 
med en ny tilgang baseret på både subjektive og objektive metoder. Metoderne omfatter 1) flere 
validerede spørgeskemaer omhandlende gastrointestinal funktion, 2) måling af segmentale 
kolorektale volumina ved hjælp af MR-scanninger, 3) måling af tarmens sekretoriske respons med 
Ussingkamre, 4) vurdering af gastrointestinale transittider ved brug af et nyt ambulant kapsel-system 
(3D-Transit) samt 5) måling af den anale sfinkters funktion og distensibilitet med ’functional lumen 
imaging probe’ (FLIP). Hypotesen var, at gennem kombinationen af disse subjektive og objektive 
metoder, ville et mere nuanceret og komplet billede af OIBD som helhed kunne opnås. 
Data blev optaget fra ét randomiseret kontrolleret forsøg, hvor 25 raske frivillige blev behandlet 
med oxycodon eller placebo i et dobbelt-blindet overkrydsningsdesign. De vigtigste resultater omfatter  
først og fremmest den succesfulde etablering af en veltolereret model af OIBD i raske frivillige, 
baseret på spørgeskema-evalueringer. Alle forsøgspersoner oplevede en væsentlig påvirkning af 
deres mavetarm-funktion med talrige OIBD-symptomer (forstoppelse, mavesmerter, oppustethed, 
etc.) under oxycodonbehandling sammenlignet med placebobehandling. I artikel I sammenlignedes 
magnetisk resonans (MR)-baserede målinger af kolorektale volumina før påbegyndelse af hhv. 
oxycodonbehandling og placebobehandling. Dette blev gjort med henblik på at undersøge, om 
metoden var reproducerbar. Metoden udviste lav variabilitet og var sågar i stand til at måle de 
ændringer, der forekom som følge af toiletbesøg. Derfor var metoden velegnet til at vurdere 
ændringer i segmentale kolorektale volumina, der fremkom som følge af opioidbehandling, hvilket 
blev undersøgt i artikel II. Her blev fastslået at volumen af coecum/colon ascendens steg betydeligt 
efter oxycodonbehandling sammenlignet med placebobehandling. I artikel III blev Ussingkammer-
teknikken anvendt til at undersøge om opioidbehandling ændrede tarmsekretion. Det blev fundet, at 
oxycodonbehandling ikke påvirkede tarmsekretionen i isoleret mucosa fra rektosigmoideum. I artikel 
IV blev de gastrointestinale transittider undersøgt, hvor vi fandt en væsentligt forlænget transittid 
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under oxycodonbehandling sammenlignet med placebobehandling i coecum/colon ascendens og 
rektosigmoideum. I coecum/colon ascendens kunne den forlængede transittid være den 
underliggende forklaring på observationen fra artikel II, at volumen tillige blev øget i dette segment 
som følge af oxycodonbehandling. Slutteligt viste en præliminær dataanalyse af den anale sfinkters 
funktion og distensibilitet stor variabilitet i datasættet, hvilket kan have udvisket en potentiel effekt af 
oxycodonbehandling og en mere avanceret dataanalyse er undervejs.  
Afslutningsvis konkluderes, at det er lykkedes at udvikle en eksperimentel model af OIBD i et 
kontrolleret miljø. Kombinationen af subjektive og objektive mål muliggør en mere dybdegående 
undersøgelse af den kliniske manifestation og underliggende patofysiologiske mekanismer af OIBD 
som helhed. 
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Chapter 1 Introduction 
1.1 Chronic pain and opioid-induced bowel dysfunction 
Pain is one of the most frequently presented symptoms in patients in the primary and secondary 
health care sector. While acute pain is a normal sensory experience that alerts the individual of actual 
or potential tissue damage, chronic pain is vastly different. Often defined as any pain lasting more 
than 12 weeks, chronic pain may originate from an initial injury or infection, or there may be a 
persistent inflammation or continuous tissue remodelling that leads to chronic pain, such as arthritis or 
diabetic neuropathy. Chronic pain is associated with decreased quality of life, and comprehensive 
socioeconomic consequences (Langley et al. 2010; Breivik 2012). In fact, the European prevalence of 
chronic pain ranges from 12% to 30% of adults (Breivik et al. 2006). In Denmark, the estimated 
number of people with chronic pain is approximately 20% (Sjøgren et al. 2009). Of the patients 
presenting with moderate to severe non-malignant chronic pain, opioids are often considered the best 
intervention to achieving adequate pain relief when treatment with paracetamol or non-steroidal anti-
inflammatory drugs (NSAIDS) have proven inadequate (Pappagallo 2001). In Denmark, 
approximately 13% of patients with chronic pain receive opioids (Kurita et al. 2012) but studies have 
shown great variation across countries with up to 90% of patients with chronic pain receiving opioid 
treatment (Benyamin et al. 2008).  
However, the analgesic effect achieved through opioid treatment comes at a cost: Adverse effects 
are common and regrettably often counterbalance the analgesic benefits. The analgesic effect is 
achieved through binding to specific opioid receptors within the central nervous system (CNS). 
Additionally, identical receptors are also expressed in the gastrointestinal (GI) tract, which are directly 
related to normal GI functions by way of the endogenous opioids (e.g. endorphins) (De Schepper et 
al. 2004). However, exogenous opioids in clinical doses saturate the endogenous opioid system in the 
GI tract and consequently disrupt normal GI function (Wood & Galligan 2004; Camilleri 2011; Holzer 
2009). This GI interference manifests as a plethora of symptoms including gastro-oesophageal reflux, 
vomiting, bloating, abdominal pain, anorexia, hard and dry stools, constipation, and incomplete 
evacuation (Figure 1).  
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Figure 1: Opioid adverse effects on the central nervous system (CNS) and the enteric nervous system (ENS).  
 
The GI symptoms related to adverse effects of exogenous opioids are collectively referred to under 
the umbrella-term ‘opioid-induced bowel dysfunction’ (OIBD) (Benyamin et al. 2008; Brock et al. 
2012). These symptoms can be severe and drastically reduce patients’ quality of life, which affects 
normal functioning and work productivity thereby carrying great socioeconomic impact (Bell et al. 
2007; Cook et al. 2007; Penning-van Beest et al. 2010; Thorpe 2001). Adverse effects of opioid use 
also occur as a result of opioid binding within the CNS where common symptoms include nausea, 
sedation, headache, confusion, dizziness, and vomiting although tolerance to these adverse effects 
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tend to develop over time. In contrast, tolerance to OIBD is rarely achieved and because opioids 
inhibit GI function at doses much lower than those needed to produce analgesia these adverse effects 
cannot be easily overcome through opioid dose reductions (Swegle & Logemann 2006; Shook et al. 
1987). In fact, opioid dosage tends to escalate over time and constipation becomes an increasing 
burden for the chronic pain patient (Pappagallo 2001). Cook et al. found that 57% of adults using 
opioids to manage non-cancer pain, reported developing constipation in association with opioid use 
(Cook et al. 2008). Development of constipation as a result of opioid treatment may lead to 
obstipation, colonic distension, ileus and even perforation (Dubinsky 1996). As a result, upwards of a 
third of patients treated with opioids report missing treatment, decreasing treatment, or even opt to 
completely discontinue treatment in order to improve bowel function. This impact on patient 
compliance naturally is a great obstacle in the attempt to provide adequate pain management as the 
resulting analgesic suboptimal treatment further impairs quality of life (Kurz & Sessler 2003; Bell et al. 
2009; Cherny et al. 2001; Wirz 2005).  
To overcome these adverse effects and increase patient compliance laxative co-administration is 
common in patients treated with opioids for chronic pain. Accordingly, Pappagallo et al., showed that 
88% of 76 patients treated with opioids used at least one laxative and 58% of 76 patients used two or 
more different laxatives (Pappagallo 2001). The challenge with laxative use in the treatment of OIBD 
is that conventional laxatives (described in detail later) do not target the underlying pathophysiological 
mechanism, namely the binding of exogenous opioids to the opioid receptors in the enteric nervous 
system (ENS), and thus have limited effect on manifest OIBD. 
1.1.1 The enteric nervous system (ENS) 
Many aspects of OIBD have yet to be described and understood in detail. For example, it is not clear 
whether the bowel dysfunction is a pan-enteric phenomenon or if it primarily is the colon that is 
affected. Obviously, the lack of knowledge complicates effective alleviation of OIBD and the treatment 
options are mainly symptomatic and rely heavily on laxative use (although these often display 
relatively poor efficacy) for constipation caused by opioid use. The primary mechanism of action of 
conventional laxatives is mainly targeted at the colon, relying on increasing the osmotic gradient 
and/or stimulating the colonic musculature. Because OIBD likely affects peripheral opioid receptors 
throughout the entire GI tract, treatment with laxatives displays relatively poor efficacy. Hence, a 
thorough understanding of GI physiology and opioid pharmacology is imperative to advance our 
understanding of OIBD. 
 
The GI tract is innervated extrinsically by autonomic fibres from the CNS and intrinsically from the 
ENS (Figure 2). Exceptions include the striated muscle fibres in the oesophagus and the external 
anal sphincter, as these are innervated by spinal somatic fibres and somatic fibres from the pudendal 
nerve (S2-S3), respectively. The vagus nerve supplies parasympathetic innervation for the stomach, 
the small intestine, and proximal colonic segments from caecum to splenic flexure. The distal colonic 
segments, rectum and anal canal are parasympathetically innervated from the sacral roots (S2-S4) 
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(Rostgaard et al. 2006; Gudsoorkar & Quigley 2014). The stomach receives sympathetic innervation 
from the splanchnic thoracic nerves, which connect with postganglionic fibres from the coeliac plexus. 
The small intestine is primarily innervated by the superior mesenteric plexus and the distal colon is 
innervated by the inferior mesenteric plexus (Rostgaard et al. 2006).  
 
Figure 2: Schematic representation of the nervous innervation of the gastrointestinal tract.  
 
While sympathetic stimulation reduces peristaltic activity and causes splanchnic vasoconstriction, 
parasympathetic stimulation increases peristaltic activity, secretion and vasodilatation. The primary 
excitatory neurotransmitters for the sympathetic and parasympathetic fibres are noradrenaline and 
acetylcholine. In effect, the afferents modulate local effector systems including musculature, secretory 
glands, and blood vasculature (Costa & Brookes 1994; Gershon 1981). These effector systems are 
controlled by motor neurons in the ENS transducing neural input originating from local sensory 
neurons, although some also receive input from the CNS via autonomic (both sympathetic and 
parasympathetic) pathways (Aziz & Thompson 1998).  
The enteric nervous system is known as the ‘brain of the gut’ is comprised of some 200–600 
million neurons and even more glia cells, placed in the gut wall along the entire GI tract (Furness et al. 
2014). Here, they form complex interactions between sensory neurons, motoneurons, and 
interneurons exchanging information, constantly monitoring and controlling the GI effectors systems. 
The ENS motor neurons are divided into two principal types: the musculomotor neurons, which 
control the muscularis externa and the muscularis mucosae and the secretomotor neurons, which 
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innervate the different intestinal secretory glands (Wood 2010). The myenteric plexus is aptly named 
after its anatomical location between the longitudinal and the circular muscle layers along the GI tract 
as well as its control of the motor activity within the gut (Figure 3).  
 
Figure 3: Schematic representation of the anatomical location of the myenteric and submucosal plexus in the gut 
wall.  
 
The submucosal plexus is located closer to the gut lumen in the submucosa. Here, it controls gut 
secretion and gut absorption. Furthermore, the ENS possesses its own pacemaker system of cells of 
Cajal that ensures continuous gut peristalsis. The cells of Cajal are electrically coupled through gap 
junctions and generate oscillating ‘slow wave’ activity (Huizinga et al. 2013).  
1.1.2 Opioid pharmacology 
Within both the ENS and the CNS opioids exert their function through binding to specific opioid 
receptors. Four different receptors display affinity towards opioids, namely the μ-opioid receptor 
(MOR), the κ-opioid receptor (KOR), the δ-opioid receptor (DOR), and the opioid receptor like-1, 
which displays 65% sequence homology to the other receptors (Fioravanti & Vanderah 2008). The 
analgesic effect of opioids stems from binding to receptors within the CNS but the opioid receptors 
are widely distributed, both centrally and peripherally, as all receptors are synthesised within the 
dorsal root ganglia and from here, the receptors are transported via axons to nerve terminals in the 
periphery or in central structures (Epstein & Stein 1995).  
The opioid receptors are G-protein coupled receptors and opioid binding to the receptor results in 
inhibition of voltage-gated ion channels, by impairing the enzymatic conversion of adenosine 
triphosphate to cyclic adenosine monophosphate (cAMP) (Figure 4). Cyclic AMP is an important 
regulator of normal cellular function and its inhibition leads to a decrease in the release of 
neurotransmitters such as glutamate, substance P, and calcitonin gene-related peptide (Trescot et al. 
2008; Sharma et al. 1975). The resulting decrease in neuronal activity and release of 
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neurotransmitters alters both GI function via the ENS and pain perception via the CNS although 
evidence of cross-talk between these nervous systems exist (Galligan & Burks 1983; Thörn et al. 
1996).  
 
Figure 4: Simplified representation of the opioid mechanism of action at the presynaptic terminal. Opioid binding 
at the presynaptic terminal to G-protein coupled opioid receptors causes part of the G-protein to inhibit voltage-
gated ion channels or to inhibit the enzymatic conversion of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate via adenylate cyclase. Reduced ion influx further reduces the amount of intracellular cyclic 
adenosine monophosphate (cAMP). Ultimately, the overall effect is a reduction in the release of 
neurotransmitters including calcitonin-related peptide, glutamate, and substance P. Orange lines indicate 
inhibition.
 
From a clinical standpoint, the MOR is of particular importance because most commonly prescribed 
opioids display high affinity for the this receptor and because of its abundance in the GI tract (Sternini 
et al. 2004). In the human gut, MORs are primarily located on neurons in the myenteric and 
submucosal plexus and on mononuclear immune cells in the lamina propria where they are activated 
by endogenous ligands including enkephalins, endorphins, and dynorphins under physiological 
conditions (Greenwood-Van Meerveld et al. 2004; Sternini et al. 2004).  
1.1.3 Gut motility 
Gut motility is organised in a way that produces peristaltic contractions that 1) move ingested food in 
the form of a bolus from mouth to anus, 2) break up large food particles into smaller particles, 3) 
ensure adequate mixing of digestive enzymes with the bolus, and 4) allow sufficient mucosa-bolus 
contact for nutrient absorption. This motility is controlled from the myenteric plexus via 
neurotransmitters (e.g. acetylcholine, serotonin, vasoactive intestinal peptide, and nitric oxide) 
released from enteric neurons and excitation-contraction coupling in the circular smooth muscles. 
Acetylcholine activates the cholinergic excitatory motoneurons in the longitudinal smooth muscles, 
whereas nitric oxide and vasoactive intestinal peptide control the inhibition of non-cholinergic 
inhibitory motoneurons in the circular smooth muscles. Effectively, this allows the coordination of the 
Presynaptic terminal Voltage-gatedion channelOpioid receptors
G G
G
G
G
Opioi
d
Substance P
Glutamate
Calcitonin
gene-related 
peptide
cAMP
Enzyme
G
ATP
 
23 
contractile and propulsive gut motility to be determined by a balance between facilitatory effects of 
acetylcholine and inhibitory effects of nitric oxide and vasoactive intestinal peptide (Wood & Galligan 
2004; Sarna & Otterson 1990). As previously mentioned, the ENS has its own pacemaker system 
through networks of interstitial cells of Cajal. The oscillating slow wave activity generated by the 
interstitial cells of Cajal is independent of neural or hormonal input and the slow waves are conducted 
to muscle fibres in the circular and longitudinal muscle layers. Each muscle cell is individually 
activated by the pacemaker network through gap junctions because cell-cell propagation is not 
possible. Depolarization of the smooth muscle cells eventually opens voltage-gated calcium channels 
causing generation of action potentials, which ultimately leads to muscle contraction (Sanders et al. 
2014; Sanders et al. 2012). The frequency of slow waves is different between GI regions and 
segments. The gastric antrum has a contraction frequency of approximately 3 contractions per minute 
(cpm), the duodenum 11–12 cpm, the proximal small intestine 11 cpm, which declines to 7-8 cpm 
distally, and the colon has 3-6 cpm. The contraction frequency in the GI tract does not increase 
beyond the pace set by the slow waves. Inhibitory neurons within the ENS can decrease the slow 
wave pace by preventing slow waves from causing a contraction. This also determines the length of 
the segment the contractions cover (Sanders et al. 2012; Wood 2009). 
The ENS changes motility pattern based on the digestive state of the individual. Five to ten 
minutes after ingesting a meal, the postprandial state is activated, which lasts for the duration that 
food content remains in the stomach. Subsequently, the postprandial state cease and is replaced by 
the fasting state. During the fasting state, the migrating motor complexes (MMC) occur. The function 
of the MMC is thorough emptying of the stomach and small intestine, in order to prepare these for the 
next meal. While the ENS controls both motility patterns, the signal to switch from one to the other 
comes from the vagal nerve that detects distension of the stomach (Furness et al. 2014; Cassilly et al. 
2008; Thomas 2008).  
1.1.3.1 Opioid effects on motility 
Opioid treatment alters oesophageal motility by inducing non-propulsive peristaltic contractions and 
incomplete relaxation of the lower oesophageal sphincter, which increases the risk of gastro-
oesophageal reflux and dysphagia (Kraichely et al. 2010). Gastric emptying is prolonged during opioid 
treatment likely as a result of decreased gastric contractility (Rozov-Ung et al. 2014) while small 
intestinal and colonic effects of opioid treatment include increased resting contractile tone of the 
circular muscle layer coupled with a suppressed tonic inhibition of the muscle tone. Together, this 
causes an increased circular muscle tone (Frantzides et al. 1992; Telford et al. 1989; Sarna & 
Otterson 1990). Additionally, enhanced rhythmic contractions and high-amplitude non-propulsive 
phasic contractions is observed, which causes increased segmental spastic tone and reduced 
propulsive motility (Figure 5) (Thomas 2008; De Schepper et al. 2004; Kraichely et al. 2010). 
Clinically, these effects manifest as constipation, abdominal cramps, and bloating. These effects 
cause stasis of intestinal content, which prolongs the time for passive absorption of fluids. This 
naturally results in harder and drier stools that are difficult to pass. 
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Figure 5: Schematic illustration of the dysfunctional gut motility during opioid-induced bowel dysfunction (OIBD). 
Under normal conditions propulsive movements occur through well-coordinated muscle contraction and 
relaxation. In OIBD there is an increased tonic muscle tonus and dyscoordinated muscle contractions that result 
in non-propulsive movements.  
1.1.4 Gut secretion 
Gut secretion is a pivotal factor in ensuring optimal conditions for digestion, absorption of nutrient, and 
propulsion of intestinal content. Every day the GI tract secretes an impressive volume of fluid of 
approximately 8-9 L (approximately 2 L saliva; 2.5 L gastric juice; 0.5-1 L bile; 1.5 L pancreatic juice 
and 1.5-2 L small intestinal secretions) (Barrett & Keely 2000; De Luca & Coupar 1996). In 
comparison, very little fluid is expelled with faeces under normal conditions, which means that the 
mechanisms controlling fluid and electrolyte secretion and absorption are closely regulated. Gut 
secretion relies on the osmotic gradient across the enterocyte because water cannot be actively 
secreted. To establish and control this gradient, several electrolytes are involved of which the most 
important are chloride, sodium, and bicarbonate. For example, active transport of chloride into the gut 
lumen will push the osmotic gradient to increase passive water transport into the gut lumen as well. 
Because chloride secretion is the major determinant of mucosal hydration excessive or insufficient 
secretion leads to conditions such as secretory diarrhoea or cystic fibrosis (Murek et al. 2010; Sidorov 
1976).  
One of the most prominent regulators of chloride secretion is the cystic fibrosis conductance 
regulator (CFTR). This is an apical cAMP-activated channel that regulate chloride secretion into the 
gut lumen either by direct phosphorylation of the regulatory R domain (chiefly by protein kinase A) 
and subsequent ATP hydrolysis at the nucleotide binding domain or by transporting additional CFTR 
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to the membrane (Figure 6) (Barrett & Keely 2000). The primary intestinal expression of CFTR 
occurs in the crypt and to a lesser extent in the villus itself. The pathogenesis of hereditary cystic 
fibrosis is based on mutations of the CTFR gene. Accordingly, patients with cystic fibrosis are 
predisposed to the development of chronic constipation (Grubb & Gabriel 1997).  
 
Figure 6: Important regulators of gut secretion. The principal chloride driver is the cystic fibrosis conductance 
regulator (CFTR). The CFTR is primarily activated by cyclic adenosine monophosphate (cAMP), which induces 
phosphorylation (P) of the regulatory R domain by way of protein kinase A (PKA) and subsequent ATP hydrolysis 
of the nucleotide binding domain. Another important chloride regulator is the chloride channel type-2 (ClC-2), 
which is also found in the apical enterocyte membrane. The Na+-K+-ATPase, the Na+-K+-2Cl- cotransporter 
(NKCC cotransporter), and potassium channels maintain a sustained favourable electronic gradient across the 
enterocyte. 
 
The chloride channel type-2 (ClC-2) is another prominent chloride regulator. Primarily located on the 
apical surface of intestinal enterocytes ClC-2 its physiological contribution the small intestinal chloride 
secretion have yet to be determined. Knockout ClC-2 mice (-/-) do not suffer from neither GI 
obstruction nor increased mortality. Furthermore, double-knockout mice, where both genes for the 
CFTR and the ClC-2 were deleted did not exacerbate the symptoms observed with single knock-out 
of the CTFR gene (Zdebik et al. 2004). Nevertheless, Bijvelds and colleagues demonstrated evidence 
of cross talk between the ClC-2 and CFTR in a study investigating the effect of the selective ClC-2 
agonist lubiprostone. Here, the secretory response to lubiprostone in tissue from healthy controls was 
compared to patients with cystic fibrosis. It was found that while lubiprostone significantly induced a 
secretory response in healthy tissue, it failed to do so in tissue with mutations to the CFTR (Bijvelds et 
al. 2009). 
The chloride efflux into the gut lumen will gradually depolarise the enterocyte. However, this is kept 
in check by basolateral potassium channels and the Na+-K+-ATPase that counterbalance the chloride 
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efflux by maintaining a state of hyperpolarization (Mandel et al. 1986). Furthermore, the Na+-K+-2Cl- 
cotransporter ensures chloride basolateral chloride uptake to provide a substrate for sustained apical 
chloride secretion (Barrett & Keely 2000). 
 
1.1.4.1 Opioid effect on secretion 
During opioid treatment gut secretion is reduced as a direct result of inhibited cAMP and vasoactive 
intestinal peptide production. Subsequently, a general decrease in gut secretion of intestinal fluid 
secretion occurs, which leads to drier and harder stools. Furthermore, as gut motility is also 
dependent on volume inside the lumen via local stretch reflexes, decreased secretion (and volume) 
will also lead to a decrease in peristalsis (Furness & Costa 1987; Huizinga & Lammers 2009).  
 
1.2 Treatment of OIBD 
Satisfactory management of OIBD remains a challenge (Dorn et al. 2014; Bell et al. 2009). The 
current recommendation of combining laxatives with dietary changes and lifestyle changes is better 
suited for the treatment of e.g. chronic idiopathic constipation, where the underlying pathology is not 
due to opioid exposure. As it stands, this treatment strategy is often inadequate in the alleviation of 
OIBD and is even worsened because the majority of patients receiving chronic pain treatment suffer 
from co-morbidities resulting in e.g. less mobility (Diego et al. 2011; Dorn et al. 2014). Furthermore, 
past treatment of OIBD has revolved around normalization of spontaneous bowel movements 
(SBMs), leaving the remaining symptoms (e.g. straining, bloating, abdominal pain) unmonitored and 
untreated. The following sections are intended to provide an overview of the current treatment 
strategies and pharmacological approaches.  
 
1.2.1 Laxatives 
Laxatives are commonly prescribed to treat constipation and they generally exert their function by 
altering the composition and volume of the intestinal content, by stimulating gut motility, or through 
alterations of the ion and fluid transport across the intestinal epithelium. Accordingly, they are divided 
into different sub-groups based on their mechanism of action. These include the stimulant laxatives 
(e.g. bisacodyl, senna) that directly stimulate gut motility while inhibiting absorption of fluid and 
electrolytes from the gut lumen, which increases content volume. This in turn activates local stretch 
receptors and promotes further motility increase. The osmotic laxatives (e.g. magnesium, lactulose, 
polyethylene glycol) draw fluid into the gut lumen to increase peristalsis. An additional benefit is 
achieved from the increased luminal fluid in its stool softening effect. Electrolyte solutions with non-
absorbable macrogols are laxative by way of their osmotic capacities. The electrolyte solutions are 
composed in a way that reduces fluid and electrolyte loss. The bulking agents (e.g. methylcellulose, 
psyllium) ease constipation by increasing the volume of stool and making it easier to pass. Finally, 
stool softeners are anionic surfactants that enable enhanced incorporation water and fats into the 
 
27 
stool, making it softer and traverse the GI tract with greater ease. Studies comparing different laxative 
regimens in patients with opioid-induced constipation are very limited and newer therapeutic agents 
are not routinely compared with established evidence-based treatment options, but rather to placebo. 
Although traditional laxatives have proven useful in inducing bowel movements, there is no convincing 
evidence to suggest which laxative is optimal for OIBD (Camilleri et al. 2014; Candy et al. 2011; 
Ahmedzai & Boland 2010). The few clinical trials comparing laxatives conclude that routinely used 
laxatives have comparable, suboptimal efficacy for opioid-induced constipation (Ruston et al. 2013; 
Agra et al. 1998; Freedman et al. 1997; Ramesh et al. 1998). This observation is supported by a 
study where chronic pain patients reported their bowel habits before and after initiating treatment with 
oral opioids with concomitant laxative use. Approximately half of the patients were using two or more 
laxatives. In the run-in 70% of patients reported ≥ 3 SBMs/week. After initiating oral opioid therapy, 
55% reported having ≥ 3 SBMs/week yet interestingly, 81% still reported constipation as an opioid-
induced adverse effect (Bell et al. 2009). This emphasises the point that monitoring of SBMs is an 
inadequate proxy for constipation and even more so for the multifaceted symptomatology of OIBD. 
The widespread application of SBMs as the primary outcome measure in previous studies also 
severely hinders comparison of new literature with existing in terms of the remaining clinical 
presentations of OIBD.  
1.2.2 Chloride channel activator 
Lubiprostone is derived from prostaglandin E1 and its mechanism of action relies on specific 
activation of the apical ClC-2 chloride channels in enterocytes (Figure 6) to improve stool consistency 
(Lacy & Chey 2009; Owen 2008). It was originally indicated for chronic constipation and constipation-
predominant irritable bowel syndrome, where its efficacy was determined based on increased SBMs. 
Moreover, it was found that stool consistency, straining, bloating and severity of opioid-induced 
constipation improved as well (Wong & Camilleri 2011; Owen 2008). Subsequently, lubiprostone was 
approved in the US for treatment of opioid-induced constipation in adult patients with non-cancer pain 
where normal laxative treatment is inadequate (Camilleri et al. 2014; Mazen Jamal et al. 2012). 
1.2.3 Selective 5-HT4 agonist 
Prucalopride is a selective 5-HT4 agonist that alters colonic motility via serotonin 5-HT4 receptors in 
the gut. Primarily indicated and approved in many countries for chronic idiopathic constipation in 
females, but has demonstrated efficacy in opioid-induced constipation patients (Sloots et al. 2010). 
However, the effect was only significant at two weeks of treatment but not after four weeks and the 
drug is not approved for opioid-induced constipation. Furthermore, a randomised controlled trial 
comparing prucalopride to conventional treatment with macrogol in chronically constipated females 
found macrogol to be generally better tolerated and at least as efficacious as prucalopride (Cinca et 
al. 2013). 
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1.2.4 Tapentadol 
Another approach to minimise the GI adverse effects of opioid treatment is through dual action drugs. 
One of these, tapentadol, is an opioid with classic MOR agonistic properties but with simultaneous 
action as a noradrenaline reuptake inhibitor. This dual action results in an additional analgesic effect 
(Tzschentke et al. 2009; Wade & Spruill 2009). It is efficacious in treating nociceptive and neuropathic 
pain conditions although data on its efficacy in the treatment of malignant pain is limited. The dual 
action also means that for an equianalgesic dose, less MOR agonism is required, which in turn 
improves the adverse effects profile (Afilalo & Morlion 2013). Accordingly, animal studies have shown 
less adverse effects on the CNS including nausea and vomiting from tapentadol use compared to 
equianalgesic doses of morphine (Tzschentke et al. 2009). In human trials, tapentadol compared to 
oxycodone exhibited improved GI tolerability and improved compliance with less treatment 
discontinuations (Wild et al. 2010; Buynak et al. 2010; Steigerwald et al. 2013; Wade & Spruill 2009). 
 
1.2.5 Opioid antagonists 
Where the other treatment strategies attempt to alleviate existing adverse effects or produce less 
adverse effects, opioid antagonists is a much more direct approach where the underlying 
pathophysiology is targeted specifically. Selective antagonism of MORs in the periphery should 
prevent the majority of all GI-related adverse effects. Several different drugs exist in this class and are 
distinguished primarily on grounds of their respective pharmacokinetic properties. 
The archetype opioid antagonist is naloxone, which is a pure antagonist with no agonistic 
properties. Naloxone has been used widely as a highly effective antidote in the treatment of opioid 
overdose because of its very high affinity for the MOR. Given intravenously or intramuscularly, 
naloxone will antagonise both central and peripherally mediated opioid effects. Although oral 
naloxone undergoes extensive first-pass metabolism it is capable of crossing the blood-brain-barrier 
where it will reverse the central analgesic effects of opioid treatment. This is the primary reason for 
the absence of a stand-alone orally formulated naloxone product to treat OIBD (Vondrackova et al. 
2008; Meissner et al. 2009). 
Hence, successful use of opioid antagonists requires effective peripheral restriction. One attempt 
to achieve this property is based on the combination of prolonged release oxycodone and prolonged 
release naloxone in a 2:1 ratio tablet. The idea with this drug is to prevent OIBD from occurring 
through MOR antagonism in the periphery while preserving the analgesic effect of oxycodone in the 
CNS. The already low bioavailability of oral naloxone is further decreased by its relatively low dose 
and the fact that it is a prolonged release formulation, thereby rendering central antagonism unlikely 
(Smith et al. 2012). Studies have shown promising analgesic efficacy as well as improvement in OIBD 
symptoms (Burness & Keating 2014; Leppert 2013a; Leppert 2013b). In patients with hepatic 
impairment the bioavailability of naloxone may be enhanced because naloxone is metabolised in the 
liver (Leppert 2013a; Kraft 2008). Still, the primary drawback of this combination of prolonged release 
oxycodone and prolonged release naloxone is the fixed combination of oxycodone and naloxone in a 
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2:1 ratio in doses ranging from 5 mg oxycodone + 2.5 mg naloxone to 80 mg oxycodone + 40 mg 
naloxone. The fixed combination demands opioid rotation for patients treated with other opioids, and 
although recommendations are available this may be difficult outside specialist centres (Drewes et al. 
2013). 
Alvimopan is an oral peripherally acting MOR antagonist capable of increasing SBMs in patients 
with OIBD (Paulson et al. 2005; Roberts et al. 2002; Camilleri 2005). Because of cardiovascular 
safety concerns its development has been paused. However, the US Food and Drug Administration 
have approved the use of alvimopan in the treatment of post-operative ileus following partial bowel 
resection with primary anastomosis in hospitalised patients. Again, its applicability is of limited benefit 
to the general OIBD population because alvimopan is only registered in the US.  
Naloxegol is a PEGylated naloxone moiety. Here, PEGylation of naloxone entails the attachment 
of a polyethylene glycol chain (Roberts et al. 2002). This chain is not capable of cross the blood-
brain-barrier, which restricts naloxegol to the periphery where the naloxone part of naloxegol can act 
as a MOR antagonist (Webster et al. 2013). Naloxegol is administered orally once a day, and is 
advantageous in its ability be added to existing opioid therapy and thereby also allows for opioid 
rotation. It has proven efficacious compared to placebo on a number of different outcome measures, 
including OIBD symptoms and is generally well-tolerated with an acceptable safety profile (Chey et al. 
2014; Webster et al. 2014; Bui et al. 2014). 
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Chapter 2 Hypotheses and aims 
In order to describe the underlying pathophysiological mechanisms of OIBD in a controlled 
environment we developed an experimental model of OIBD in healthy volunteers (HVs) treated with 
prolonged-release oral oxycodone. It was hypothesised that assessments of gut function with 1) 
questionnaires, 2) MRI, 3) Ussing chambers, 4) the 3D-Transit system, and 5) FLIP would be 
sensitive in the detection of any alterations brought on by this experimental model of OIBD in HVs. 
Hence, the aims were: 
 
 
I. To describe the inter-individual and intra-individual variability of segmental colorectal MRI 
volumes between two observations in healthy subjects and the change in segmental 
colorectal volume distribution before and after defecation (paper I). 
 
II. To investigate how oxycodone treatment, compared to placebo, affects sensitivity to somatic 
painful stimuli, bowel function assessed with questionnaires, and segmental colorectal 
volumes assessed with MRI (paper II). 
 
III. To describe electrogenic epithelial ion transport in isolated mucosal biopsies from the 
rectosigmoid colon following five-day in vivo treatment with oxycodone compared to placebo 
and during in vitro addition of morphine (paper III). 
 
IV. To evaluate how oxycodone treatment, compared to placebo, affects GI symptoms assessed 
by questionnaires and regional GI transit times using the 3D-Transit system (paper IV). 
 
V. To evaluate how oxycodone treatment, compared to placebo, affects anal sphincter function 
and distensibility at rest and during challenge testing. 
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Chapter 3 Materials and methods 
The present dissertation is based on data from a single trial named MULTIPAIN6-2013 (sub-study 
1b). The trial objective was to develop and validate a reliable model of experimentally induced OIBD 
in healthy volunteers where assessment of gut motility, gut secretion, and sphincter function were 
possible. These parameters are assessed by measuring 1) patient reported questionnaires, 2) 
segmental colorectal volumes using a novel MRI-based technique, 3) electrogenic epithelial ion 
transport in viable colonic tissue using Ussing chambers, 4) gastrointestinal transit times with the 3D-
Transit system, and 5) anal sphincter function using FLIP. 
 
The trial was approved by the local ethical committee of the Northern Jutland Region (N-20130030) 
and by the Danish Health and Medicines Authority (EudraCT no.: 2013-001540-60). The trial was 
covered by Danish Data Protection Agency under the umbrella approval of the Northern Jutland 
Region, registered with www.clinicaltrials.eu under the EudraCT number supplied above, and 
conducted in compliance with Good Clinical Practice (CPMP/ICH/135/95), designated Standard 
Operating Procedures, the Danish Health and Medicines Authority, the Research Ethics Committee in 
Denmark, and within the principles of the Declaration of Helsinki (amended by the 52nd General 
Assembly, Edinburgh, Scotland, October 2000, clarified by the General Assembly in Washington 
2002, Tokyo 2004, and Seoul 2008 as outlined herein. 
All subjects gave written informed consent prior to enrolment in the trial. Data was collected 
between April 2014 and February 2015 at the Mech-Sense research facilities at Department of 
Gastroenterology & Hepatology and Department of Radiology, Aalborg University Hospital, Aalborg, 
Denmark. 
3.1 Study population 
Twenty-five healthy male volunteers with neither history nor current symptoms of gastrointestinal 
disease were included in the study. All subjects underwent a screening session prior to enrolment in 
the study where a physician evaluated their medical history, ensured that all inclusion and no 
exclusion criteria were fulfilled, conducted a physical examination, and enrolled subjects if eligible.  
Inclusion criteria were:  
1) Signed informed consent declaration. 
2) Capable of reading and understanding Danish. 
3) Male of Northern European descent. 
4) Understand what the study entails. 
5) Aged 20-60 years. 
6) Healthy. 
7) Opioid naïve.  
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Exclusion criteria were: 
1) Known hypersensitivity towards opioids.  
2) Participation in any other studies within 14 days of enrolment.  
3) Planned medical/surgical treatment within the study duration.  
4) Need to operate heavy machinery or motor vehicles within the study duration.  
5) Previous or current drug abuse. 
6) Non-removable piercings or metal implants. 
7) Daily alcohol consumption. 
8) Daily nicotine consumption. 
9) Known disease that may influence the results. 
10) Use of prescription medicine and/or herbal medicine. 
 
3.2 Induction of experimental OIBD 
3.2.1 Study design and procedures 
Sub-study 1b of MULTIPAIN6-2013 serves to validate the model of OIBD in healthy volunteers. It is 
designed as a two-armed randomised, double-blinded, placebo-controlled, crossover trial in 25 
healthy volunteers. The subjects participated in two separate five-day periods, where they were 
randomised to either oxycodone or placebo in the first study period and then crossed over to the other 
treatment in the last period. A wash-out period of minimum 9 days was enforced to minimise the risk 
of a carry-over effect between treatment periods. 
 
Figure 7: Trial design overview. 
 
On day 1:  Baseline assessments began with measurement of segmental colorectal volumes with 
MRI at the department of Radiology and when completed, the subjects returned to the Mech-Sense 
laboratory at the department of Gastroenterology and Hepatology, to complete the remaining 
experimental procedures. These included the following:  Pain response to muscle pressure algometry, 
biopsy acquisition (for the Ussing chamber experiments), and all questionnaires. Subsequent to the 
completion of baseline measurements, the first dose of oxycodone/placebo was administered 
according to the randomisation procedure (Figure 8). The 3D-Transit capsule was swallowed and the 
second dose handed out for self-administration at a given time point. At home, the Bristol stool form 
scale (BSFS) questionnaire was continuously filled out every time the subject has a bowel movement. 
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A specific 3D-Transit diary was filled out continuously detailing the time points on which the subjects 
1) had meals, 2) had bowel movements, 3) went to bed, 4) woke up, 5) changed battery, 6) watched 
TV, 7) used a computer, and 8) used transportation. The four first parameters were used in the data 
interpretation as they had the potential to affect gut motility. The four latter parameters were involved 
in data quality as battery changes produced loss of signal and TV/computer could interfere with 
electromagnetic noise while use of transportation could produce distinct movement artefacts. 
 
On day 2: Pressure algometry, PAC-SYM questionnaire, and administration of the third dose. The 
fourth dose was handed out for self-administration at a given time point. At home, the BSFS 
questionnaire and 3D-Transit diary was filled out continuously. 
On day 3: Pressure algometry, PAC-SYM questionnaire, and administration of the fifth dose. The 
sixth dose was handed out for self-administration at a given time point. At home, the BSFS 
questionnaire and 3D-Transit diary was filled out continuously. 
On day 4: Pressure algometry, PAC-SYM questionnaire, and administration of the seventh dose. 
The eighth and ninth dose was handed out for self-administration at a given time point. At home, the 
BSFS questionnaire and 3D-Transit diary was filled out continuously. 
On day 5: the healthy volunteers self-administered the ninth (and only) dose an hour before 
arriving at the research facility. Experimental procedures were performed: Pressure algometry, MRI, 
biopsy acquisition, and questionnaires. 
 
 
Figure 8: Experimental procedures for a given study period (Monday-Friday). The blue area in the bottom of the 
graph encircles procedures that took place out of the research facility. Subjects were instructed when to 
administer the 2nd, 4th, 6th, and 8th dose on day 1-4, and when to fill out the questionnaires by an automated text-
message service. The 3D-Transit system was worn continuously until registration of capsule expulsion.  
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3.2.2 Study medication 
Oxycodone is a semisynthetic opioid agonist, which is administered as a prolonged-release oral 
tablet, releasing oxycodone hydrochloride. It exerts agonistic effects on both peripheral and central 
opioid receptors. In controlled-release formulations it is used in cancer-related pain as well as chronic 
non-cancer-related pain problems (Riley et al. 2008). Due to its effect on the peripheral opioid 
receptors constipation is among the very commonly occurring adverse effects. Therefore, it was used 
mechanistically to induce OIBD. Placebo treatment was provided by Mundipharma Research GmbH & 
Co. KG and matched the physical appearance of prolonged release oxycodone. Treatment 
commenced with 5 mg twice daily on day 1. This dose was escalated to 10 mg twice daily on day 2 
through day 4, and 10 mg once daily on day 5 (Table 1). 
 
Table 1: Trial dose regimen. 
Day mg oxycodone/dose Doses/day Total daily dose 
1 5 mg 2 10 mg 
2 10 mg 2 20 mg 
3 10 mg 2 20 mg 
4 10 mg 2 20 mg 
5 10 mg 1 10 mg 
 
3.2.3 Pressure algometry 
Pressure algometry was conducted within each day of all treatment periods in order to determine the 
analgesic effects of the administrated opioids. All stimuli were applied by the same examiner in order 
to improve consistency of the applied stimulus (Modir & Wallace 2010). Subjects were trained in 
reporting pain using a modified visual analogue scale (VAS - a continuous scale from 0-10 with 
anchor words for every increment of 1, that allows evaluation of both non-painful (from 0-5) and 
painful (from 5-10) sensation: 0=no sensation; 1=vague perception of mild sensation; 2=definite 
perception of mild sensation; 3=vague perception of moderate sensation; 4=definite perception of 
moderate sensation; 5=pain detection threshold (first time sensation was perceived as painful); 
6=slight pain; 7=moderate pain; 8=medium pain; 9=intense pain; and 10=unbearable pain (Figure 9). 
The scale has been described in details previously and used extensively to assess pain intensity in 
several different tissues (Andresen et al. 2010; Drewes et al. 2003; Staahl et al. 2006). 
Pressure was applied on the dorsal forearm with a handheld algometer (Type 2, Somedic 
production AB, Hörby, Sweden). The force increase rate was 30 kPa/s adjusted to a probe size of 1 
cm2. Two stimulations were applied per day on day 1 to day 5; first, the subjects were instructed to 
stop the stimulation when the stimulus quality changed from non-painful to painful (i.e. when the 
subjects reported 5 on the modified VAS). Second, the subjects were instructed to stop the 
stimulation upon reaching moderate pain (i.e. a 7 on the modified VAS). Pressure was applied at the 
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midpoint of the dorsal forearm to detect the pain threshold (VAS = 5) and 2 cm proximal to this point 
to detect moderate pain (VAS = 7). The two stimulations were separated by 10 seconds. 
 
Figure 9: Quantitative sensory testing: Pressure was gradually increased on the muscles of the forearm until the 
subject rated the sensation VAS = 5 (pain threshold) and VAS = 7 (moderate pain). 
 
3.3 Assessment of OIBD 
The assessment of OIBD is complicated by its multifaceted symptomatology. Previous studies have 
relied heavily on constipation, focusing primarily on e.g. SBMs or transit times, which overlooks not 
only the remaining GI-related adverse effects, but also important aspects like patient focused 
perspectives as subjective severity and impact on quality of life. The importance of these additional 
aspects is emphasised by the fact that many opioid-treated patients report normal stool frequency, 
but still experience symptoms of OIBD (Bell et al. 2009). Therefore, a combination of subjective and 
objective assessment methods is recommended when evaluating OIBD.  
 
3.3.1 Subjective assessments 
3.3.1.1 Bowel function index (BFI) 
The Bowel Function Index (BFI) is a three-item questionnaire that has been used to evaluate and 
assess the most frequently reported symptoms of OIBD (Rentz et al. 2009). It assesses the severity 
of 1) ease of defecation, 2) feeling of incomplete bowel evacuation, and 3) patients’ personal 
judgment of constipation using a 0 to 100 numerical rating, where 0 = no problems and 100 = most 
severe problems. The main advantage of the BFI is the very brief form and precise questions. 
Furthermore, it is the only scale especially designed for opioid-induced constipation. Compared to 
other questionnaires the BFI tool is easy to use and consequently, missing data rarely occurs 
(<0.5%).  
3.3.1.2 Gastrointestinal symptom rating scale (GSRS) 
The Gastrointestinal symptom rating scale (GSRS) is composed of 15 items (epigastric pain, 
epigastric burning, gastro-oesophageal reflux symptom, belching, postprandial fullness, abdominal 
distension, early satiety, abdominal pain, the feeling of hunger, nausea, intestinal rumbling, 
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constipation, diarrhoea, loose stools and hard stools), which comprise five dimensions including 
gastro-oesophageal reflux, abdominal pain, dyspepsia, diarrhoea, and constipation. Each item is 
rated according to severity on a seven-point graded Likert-type scale, where 1 = absence of 
troublesome symptoms and 7 = very troublesome symptoms. The reliability and validity of the GSRS 
are well-documented (Dimenäs et al. 1995), and normal values for a general population are available 
(Dimenäs et al. 1996). 
 
3.3.1.3 Patients assessment of constipation symptom scores (PAC-SYM) 
The PAC-SYM is comprised of 12 items assigned to three subscales: stool symptoms, rectal 
symptoms, and abdominal symptoms. Each symptom is rated on a 5-point Likert scale. In addition, 
the PAC-SYM also contains a question about the frequency of the bowel movements during the past 
7 days. Frank et al. found internal consistency and that test-retest reliability of the final instrument was 
high. Both patients and investigators can rate severity of constipations, and these ratings by different 
groups were also found to be correlated (Frank et al. 1999). The PAC-SYM is internally consistent, 
reproducible under stable conditions, valid, and responsive to change, and provides a comprehensive 
means to assess the effectiveness of treatment for constipation or for monitoring the symptoms of 
opioid-induced constipation (Frank et al. 1999; Slappendel et al. 2006). Therefore, it may be used in 
clinical settings to assist with the disorder management, bridging the gap between clinical standards 
and non-systematic self-reports (Frank et al. 1999). 
 
3.3.1.4 Spielberger’s State-Trait Anxiety Inventory (STAI) 
The questionnaire is used the level of anxiety within each subject (Hodges & Spielberger 1969). This 
questionnaire stands out as the most effective way of measuring an individual’s anxiety level as it 
clearly differentiates between temporary ‘state anxiety’ and more general long-term quality of ‘trait 
anxiety’. The state anxiety section of this questionnaire allows for quantification of anxiety levels of a 
given subject at a particular point in time. Furthermore, the STAI questionnaire enables detection of 
differences in anxiety levels over time. Both STAIS and STAIT consist of 20 positive and negative 
item such as ‘I feel calm’ or ‘I am worried’ that the subject rates from 1 = not at all to 4 = very much 
so. 
 
3.3.1.5 Subjective Opiate Withdrawal Scale (SOWS) 
The Subjective Opioid Withdrawal Scale is a self-administered scale for grading opioid withdrawal 
symptoms. It contains 16 items (symptoms) whose intensity the patient rates on a scale of 0 = not at 
all to 4 = extremely. This scale is demonstrated to be a valid and reliable indicator of the severity of 
the opiate withdrawal syndrome over a wide range of common signs and symptoms (Handelsman et 
al. 1987). 
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3.3.2 Objective assessments 
3.3.2.1 The Bristol stool form scale (BSFS) 
The Bristol Stool Form Scale is an objective assessment of the most frequently reported OIBD 
symptom: constipation. It can partly detect parameters like stool frequency and stool consistency and 
is used as a proxy of intestinal transit time (Lewis & Heaton 1997). However, the BSFS shows only a 
moderate correlation between stool form and measured whole gut or colonic transit time in 
constipated adults. Moreover, stool frequency is a poor surrogate for transit, even in those with 
reduced stool frequency (Saad et al. 2010). In fact, determination of stool form provides a qualitative 
rather than quantitative assessment of transit.  
 
Figure 10: Bristol stool form scale. 
3.3.2.2 Assessment of colon volume (MRI) 
Assessment of gastrointestinal volumes with MRI has been applied in different contexts previously ( 
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Table 2). Aside from context these studies also vary in methodology in terms of obtaining quantifiable 
volumes from MRI scans. Some studies were based on completely manual segmentation, which is 
both time consuming and can be subject to a great deal of observer bias. Others are semi-automatic, 
which often reduces time consumption and observer bias, but due to the similarity in image intensity 
of GI organs and surrounding tissues, a fully automatic method is very difficult to develop.  
In relation to the present dissertation, a novel semi-automatic method has been developed from 
2012-2014 in collaboration with Aalborg University, Department of Health Science and Technology. 
The software has been dubbed “Colometry v. 1.0” and has demonstrated good performance in terms 
of inter-observer reliability (Sandberg et al. 2015). Segmental colorectal volumes of the 
caecum/ascending colon, transverse colon, descending colon, and rectosigmoid colon can be 
determined through manually placed regions of interest on the T2-weighted scans. These regions of 
interest are used to outline the four colon segments in each of the 35-40 coronal slices per scan. 
Within these rough outlines the software is capable of determining the exact outer boundaries of the 
colon automatically, because both colon lumen and gut wall appear dark on T2-weighted scans, 
compared to the bright signal of adjacent organs and abdominal fat. 
Colon anatomy varies substantially between subjects and in order to secure consistency, each 
region was segmented according to a simple set of guidelines: 1) The caecum/ascending colon 
included the caecum to the hepatic flexure; 2) the transverse colon is the segment between hepatic 
flexure and splenic flexure; 3) transition from descending colon to sigmoid colon exhibited the greatest 
inter-individual variability (due to the absence of any clear/consistent anatomical bend of the colon) 
and was subsequently subject to the greatest discrepancies in manual segmentation. This was 
resolved by implementing a feature to the Colometry software placing a horizontal guideline that 
intersected the left anterior iliac spine. This line was used as the boundary between the descending 
and sigmoid colon. Hence, the descending colon was defined between splenic flexure and horizontal 
guideline, whilst 4) the rectosigmoid colon was defined between horizontal guideline and anus. The 
observer requires approximately 20 minutes to define the regions of interest for all 35-40 contiguous 
slices in an examination and the subsequent determination of volumes by the Colometry software is 
completed in 2-3 minutes. 
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Figure 11: Two angles of the same fully segmented abdominal MRI scan series with the Colometry v. 1.0 
software. (A) Frontal view. (B) Frontal view with forward tilt. 
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Table 2: List of studies on MRI-based determination of gastrointestinal (GI) volumes listed in descending order 
based on year of publishing.   
Authors Population GI segments Automation Context 
(Murray et al. 2015) 18 HVs Stomach Manual 
Effect of aerated drinks on 
gastric distension. 
(Sandberg et al. 
2015) 
4 HVs Colon 
Semi-
automatic 
Inter-observer reliability of 
semi-automatic method. 
(Pritchard et al. 2014) 
75 HVs 
25 IBS-D 
patients 
Colon Manual 
Postprandial effect on colon 
volumes. 
(Bharucha, Fidler, et 
al. 2014) 
43 HVs 
Stomach, 
small intestine, 
colon 
Manual + 
Semi-
automatic 
Effect of erythromycin on 
gastric emptying. 
(Bharucha, Karwoski, 
et al. 2014) 
20 HVs 
29 dyspeptic 
patients 
Stomach 
Semi-
automatic 
Comparison of semi-
automatic technique with 
manual techniques. 
(Murray et al. 2014) 16 HVs 
Stomach, 
small intestine, 
colon 
Semi-
automatic 
Impact of fructose and 
fructans ingestion on GI 
volumes. 
(Marciani et al. 2014) 24 HVs 
Stomach, 
small intestine, 
colon 
Manual + 
Semi-
automatic 
Effect of PEG dosing on GI 
volumes. 
(Placidi et al. 2012) 18 HVs 
Stomach, 
small intestine, 
colon 
Semi-
automatic 
Effect of loperamide on gut 
water distribution in a 
mannitol model of secretory 
diarrhoea 
(Di Palma et al. 2011) 
12 HVs 
20 IBS 
patients 
Rectum Manual 
Comparison of rectal 
volume in IBS patients vs. 
HVs. 
(Rubesova et al. 
2009) 
83 foetuses Colon Manual 
Volume of the normal foetal 
colon. 
HVs: healthy volunteers; IBS: irritable bowel syndrome; IBS-D: diarrhoea-predominant irritable bowel syndrome. 
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3.3.2.3 Assessment of gut secretion (Ussing chamber) 
The Ussing chamber is a powerful, yet simple technique to assess ion transport across tissues. 
Several studies have investigated human colonic biopsies and ion transport (Wallon et al. 2005; 
Kaltoft et al. 2010; Kleberg et al. 2012). However, the literature is very limited on the effects of opioids 
on gut secretion in human tissue (  
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Table 3). The studies that do exist investigate the effect of direct opioid application to intestinal tissue 
in vitro (Sun et al. 2011; Burleigh 1991), while no studies exist where human subjects are treated with 
opioids in vivo with subsequent Ussing chamber experiments on isolated tissue. Hence, in the 
present context we wish to further our understanding of the underlying mechanisms of opioid-induced 
alterations in gut secretion and to evaluate the contribution of decreased gut secretion during 
oxycodone treatment to the collective development of OIBD. To do so, a series of compounds were 
added to extracted mucosal biopsies with either a known stimulatory effect (prostaglandin E2 (PGE2) 
and theophylline) or an inhibitory effect (ouabain and possibly morphine). These compounds have 
previously been used to investigate specific secretory mechanisms. For example, addition of PGE2 
increases the amount of intracellular cAMP and theophylline inhibits enzymatic degradation of cAMP 
by phosphodiesterase (Larsen et al. 2005; Hansel et al. 2004; Kaltoft et al. 2010). Therefore, these 
two compounds should exert a pro-secretory effect by increasing the available amount of cAMP, 
which in turn can activate the CFTR channels. Activation of CFTRs increases the efflux of chloride 
ions, thereby increasing gut secretion (Barrett & Keely 2000). On the other hand, ouabain inhibits the 
Na+-K+-ATPase, which reduces the secretory capacity by limiting the ability of the enterocyte to 
maintain a favourable osmotic gradient (Dharmsathaphorn et al. 1985). The ability of morphine to limit 
gut secretion is likely not through a direct effect on gut mucosa and was added to substantiate this 
hypothesis (Burleigh 1991; Sun et al. 2011). In the present work these specific cellular secretory 
mechanisms are assessed at baseline and after oxycodone treatment and placebo treatment in order 
to determine whether oxycodone treatment induces alterations to any of these mechanisms. This will 
provide valuable information on the underlying mechanisms by which gut secretion is altered during 
opioid treatment. 
Within each study period, biopsies were taken from the rectosigmoid junction as this location was 
easily identified by an abrupt turn into the left lower quadrant (this location was found 15-20 cm from 
the anal verge, depending on inter-individual anatomical variation). Biopsies were taken at baseline 
before starting treatment and after five days of treatment. Four biopsies were taken per subject per 
day to increase the likelihood of obtaining at least one successfully mounted, viable and responsive 
biopsy at each time point. Biopsies were extracted in close proximity to each other (within five cm2). 
Slight scarring with granulation from the baseline biopsy extraction remained visible on day 5 in most 
cases and was used to ascertain biopsy extraction from a representative adjacent site.  
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Figure 12: Schematic representation of the Ussing chamber setup. A biopsy is mounted between two chambers 
that simulate the blood stream on the basolateral side of the biopsy and gut lumen on the apical side. The 
electrogenic epithelial ion transport can be measured across the biopsy. It was assumed that the chloride 
transport would decrease during OIBD.  
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Table 3: Ussing chamber studies on opioid effect listed in descending order based on year of publishing. 
GI: gastrointestinal; OR: opioid receptor; SCC: short circuit current; MOR:  μ-opioid receptor; KOR: κ-opioid 
receptor; DOR: δ-opioid receptor. 
Authors Population 
GI 
segments 
OR 
interaction 
Results 
(Sun et al. 
2011) 
Human Jejunum - 
Morphine suppresses basal SCC and 
lubiprostone can reverse this effect. 
(Fei et al. 
2010) 
Guinea pig 
and mouse 
Ileum, 
colon 
MOR 
Morphine suppresses basal SCC and 
lubiprostone can reverse this effect. 
(Fichna et al. 
2009) 
Mouse Colon KOR Salvinorin A suppresses colonic secretion. 
(Schreiber et 
al. 2004) 
Mouse Colon KOR Asimodoline suppresses colonic SCC. 
(Green et al. 
2003) 
Pig Ileum DOR Kallidin increases ileal SCC. 
(Yates et al. 
2001) 
Rat Colon - 
Stress tests increase SCC and the effect 
can be reversed with naloxone. 
(Poonyachoti 
& Brown 
2001) 
Pig Ileum DOR 
Mast cell degranulation increases SCC 
and the effect can be reversed with a 
DOR agonist. 
(Greenwood-
Van Meerveld 
et al. 2000) 
Rat 
Jejunum, 
colon 
- 
Wood creosote and loperamide does not 
affect normal SCC but can reduce SCC 
under hyper-secretory conditions. 
(Gauthier & 
Reddix 2000) 
Guinea pig Colon DOR 
DOR agonism can both supress and 
increase basal SCC depending on dose. 
(Poonyachoti 
& Brown 
1999) 
Pig Ileum DOR 
Selective DOR agonism potentiates 
secretory effects of hypersensitivity. 
(Kromer 1995) Guinea pig Colon MOR 
Loperamide has pro-secretory actions at 
the MOR. 
(Burleigh 
1991) 
Human Colon - 
Loperamide but not morphine has anti-
secretory effects in human colon. 
(Sheldon et al. 
1990) 
Mouse Jejunum 
DOR, KOR, 
MOR 
Agonists for all ORs can suppress basal 
SCC and increase G. 
(Kachur et al. 
1980) 
Guinea pig Ileum DOR 
DOR agonists reduce SCC. MOR 
agonism with fentanyl and morphine is 
ineffective. 
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3.3.2.4 Assessment of gut motility (3D-Transit system) 
The 3D-Transit system is a minimally invasive and non-radiant tool, which relies on a small wireless 
telemetric capsule that is ingested and extracorporeal portable detector with four sensors that 
continuously track the capsule’s location as it traverses the GI tract (Figure 13). Each capsule 
(dimensions: 21 mm x 8 mm, density 1.6 g/cm3) is comprised of an electromagnet and a battery. 
Battery life of the capsule is 120-180 hours at 5 Hz sampling frequency. 
 
Figure 13: The 3D-Transit system. The small capsule is easily swallowed and the monitoring system can be 
worn discretely underneath the test subjects’ own clothes for the duration of the monitoring period. 
 
As the capsule traverses the GI tract, the electromagnetic field emitted by the capsule is stored on a 
memory card in the detector. Upon completion of the examination the data stored on the memory card 
is converted into space-time coordinates (x;y;z;Φ;θ) through an iterative algorithm. The x;y;z 
coordinates refer to the distance between detector and capsule in the frontal, transversal, and sagittal 
plane, while the Φ;θ coordinates refer to the angular orientation of the capsule.  
Artefacts due to breathing and postural changes are recorded with an elastic sensor belt that is 
fixated around the subject’s chest. Movement artefacts are recorded by an accelerometer within the 
detector.  
Ultimately, the system yields provides a valid measure of gastric, small intestinal, and colonic 
transit (Worsøe et al. 2011). This magnetic capsule is swallowed and the mobile tracking system can 
be worn at home allowing healthy volunteers and patients to leave the research facility, whilst the 
system measures continuously. Because the gastric transit is largely dependent on when the subject 
has eaten, it is important for this measure that all healthy volunteers are in the fasting state when they 
arrive the research facility on day 1. Here, they ingested a small standardised meal consisting of three 
muesli bars and a cup of tap water followed by ingestion of the 3D-Transit capsule. Following the 
standardised meal the subjects were instructed to fast for another six hours. After these six hours, the 
subjects’ eating habits were not controlled further. Previous studies investigating the effect of opioid 
treatment on regional colonic motility or transit times are listed in Table 4. 
Capsule in oesophagus
Capsule
Respiratory belt
Detector in abdominal belt
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Table 4: Studies investigating the effect of opioid treatment on regional gastrointestinal transit times listed in 
descending order based on year of publishing.  
Authors Population GI segments Method Results 
(Rozov-Ung et al. 2014) 15 HVs Stomach 
Wireless motility 
capsule 
Opioid treatment 
prolongs GE 
(Jeong et al. 2012) 38 HVs 
Stomach, 
small intestine, 
colon 
Scintigraphy 
Opioid treatment 
prolongs GE and 
SBT but not CT 
(Yancey-Wrona et al. 
2011) 
10 HVs 
Orocecal 
transit time 
Breath test 
Opioid treatment 
prolongs orocecal 
transit time. 
(Smith et al. 2011) 15 HVs 
Orocecal 
transit time 
Scintigraphy 
Opioid treatment 
prolongs orocecal 
transit time 
(Gonenne et al. 2005) 74 HVs 
Stomach, 
small intestine, 
colon 
Scintigraphy 
Opioid treatment 
prolongs GE, SBT, 
and CT 
(Freye & Latasch 2000) 12 HVs 
Orocecal 
transit time 
Breath test 
Opioid treatment 
prolongs orocecal 
transit time 
(Maurer et al. 1996) 12 HVs 
Stomach, 
small intestine, 
colon 
Scintigraphy 
Opioid treatment 
does not affect GE, 
and SBT but 
prolongs CT 
(Yee et al. 1991) 10 HVs 
Stomach, 
small intestine 
Scintigraphy, 
breath test, time 
to first flatus 
Opioid treatment 
prolongs GE, SBT, 
and time to first 
flatus 
(Thorén et al. 1989) 9 HVs 
Stomach, 
small intestine 
Scintigraphy, 
breath test 
Opioid treatment 
prolongs GE and 
SBT 
(Prokop et al. 1988) 10 HVs 
Stomach, 
small intestine 
Scintigraphy, 
breath test 
Opioid treatment 
prolongs GE and 
SBT 
(Kaufman et al. 1988) 12 HVs Colon Scintigraphy 
Opioid treatment 
prolongs CT. 
GI: gastrointestinal; HVs: healthy volunteers; GE: gastric emptying; SBT: small bowel transit; CT: colonic transit. 
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3.3.2.5 Manometry and impedance planimetry (FLIP) 
Sphincter (dys)function and dyscoordination is complex and difficult to assess. Anorectal manometry 
is the most common technique for assessment of anorectal dysfunction such as impaired rectal 
contraction, paradoxical anal contraction, impaired anal relaxation, or a combination of these 
conditions. Other possible tests are defecography or the balloon expulsion test, which provides 
assessment of the patient’s ability to defecate (Rao 2007). However, in biomechanical terms the 
overall ability of a sphincter to distend or open is related to many factors including muscle tone, 
passive viscoelasticity, mechanoreceptor-mediated reflexes and perception, none of which can be 
measured sufficiently with the previous mentioned methods (Gregersen 2002). To overcome 
problems like this, methods such as the Functional Lumen Imaging Probe technique (FLIP) have 
been developed to study GI sphincters (McMahon et al. 2005). The main advantage is that it can 
distinguish between an open and closed sphincter and record the distensibility during challenge tests 
(i.e. squeezing, expulsion), whereas manometry only shows the difference between a toned and a 
relaxed sphincter (McMahon et al. 2006; Alqudah et al. 2012). Thus, the FLIP may provide useful 
information in the evaluation of anorectal dysfunction in OIBD patients.  
The functional lumen imaging probe (FLIP) is a device, which is capable of measuring the cross-
sectional area within a cylindrical bag, which is filled with electrolyte-enriched water. Within the 
cylindrical bag, a thin probe with 12 electrodes measure the distance to the bag and calculate the 
cross-sectional area in real time. On the recording unit the data output is seen in real-time. In the 
present trial the FLIP was positioned in the anal sphincter and filled with 10 mL of water. Correct 
positioning in the anal sphincter was seen as a characteristic hour glass-shape as shown in Figure 
14 because the infused water will fill the bag in area of least resistance (which in this case is on either 
side of the anal canal). Once proper positioning is ascertained, the FLIP is fixated manually during the 
actual assessment, which consists of two parts: 1) sphincter distensibility at rest and sphincter 
function during challenge testing. Sphincter distensibility at rest was carried out by infusing the bag in 
a stepwise manner with 10 mL, 30 mL, and 50 mL of water. At each step the sphincter was measured 
for 30 seconds. Sphincter function during challenge testing was carried out by infusing the bag with 
10 mL, 30 mL, and 50 mL once more but this time the subjects were instructed to actively exert 
pressure on the bag. This was done by squeezing with the external anal sphincter as much as 
possible for 10 seconds at each step. This method provides information on the coordination of the 
opening- and closing dynamics of the sphincter (Drewes 2009).  
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Figure 14: The FLIP system. A bag is connected to a computer-controlled syringe with water. The probe 
measures the cross-sectional area of a specific GI segment (in this case, the anal sphincter). 
3.4 Justification of sample size 
As this is an exploratory study accurate estimations of sample size can be difficult. Nevertheless, the 
sample size was based on the whole gut transit time measured with the 3D-Transit system, as this 
was the primary endpoint. A similar study previously investigated the same endpoints with the 3D-
Transit system in patients with neuroendocrine tumours (Gregersen et al. 2011). Here, 12 patients 
were included to estimate the effect of sandostatin on GI transit time. A mean difference of 0.47 days 
in total transit time at the end of treatment was estimated with a variance of 0.37, equivalent to a 
standard deviation (SD) of 0.61 and the effect of opioid treatment on GI transit time was expected to 
yield at least similar results. Performing power calculation to estimate a rational sample size we use a 
mean difference of 0.5 days in total transit time and a variance of 0.4. With a power of 95% and α at 
0.05 in a 2-sided t-test, the calculation estimates a sample of 19 subjects as appropriate. Since a 
difference of 0.5 days in total GI transit time may be of clinical relevance and expected to be feasible 
to obtain with the treatment, we suggest aiming for a sample of 20 subjects to obtain 95% power. 
Therefore, 25 subjects will be included in order to increase the likelihood of having sufficient complete 
data sets.  
Data output
FLIP bag
Anal sphincter
Electrodes
Recording unit
Syringe
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Chapter 4 Results 
The key results from the studies are presented in this chapter. More detailed results are found in 
paper I-IV.  
4.1 Aim I 
Aim: To describe the inter-individual and intra-individual variability of segmental colorectal MRI 
volumes between two observations in healthy subjects and the change in segmental colorectal 
volume distribution before and after defecation (paper I). 
 
Key results:  
- No significant differences between the two observations were detected for any segments (All 
P>0.05).  
- Inter-individual variability varied across segments from low correlation in caecum/ascending 
colon (intra-class correlation coefficient (ICC)=0.44) to moderate correlation in the descending 
colon (ICC=0.61), and high correlation in the transverse (ICC=0.78), rectosigmoid (ICC=0.82), 
and total volume (ICC=0.85).  
- Overall intra-individual variability was low (coefficient of variance=9%).  
- After defecation the volume of the rectosigmoid decreased by 44% (P=0.003). The change in 
rectosigmoid volume was associated with the true faecal volume (R2=0.72, P=0.02).  
 
Interpretation:  The caecum/ascending colon exhibited the most variability, potentially reflecting its 
capacity to receive and accommodate content arriving from the small intestine and store it until 
moved distally by a mass-movement. Accordingly, the inter-individual variability was lower for the 
remaining colorectal segments. Imaging of segmental colorectal volume, morphology, and faecal 
accumulation is advantageous to conventional methods in its low variability, high spatial resolution, 
and its absence of contrast-enhancing agents and irradiation. Hence, the method is suitable for future 
clinical and interventional studies as well as for characterisation of defecation physiology.  
 
4.2 Aim II 
Aim: To investigate how oxycodone treatment, compared to placebo, affects sensitivity to somatic 
painful stimuli, bowel function assessed with questionnaires, and segmental colorectal volumes 
assessed with MRI (paper II). 
 
Key results: 
- Compared to baseline, oxycodone increased pain detection thresholds by 8% (P=0.02).  
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- Oxycodone treatment induced OIBD seen as increased scores in the BFI questionnaire 
(464% increase; P<0.001), the GSRS questionnaire (37% increase; P<0.001), and the PAC-
SYM questionnaire (198% increase; P<0.001) compared to placebo.  
- Objectively, stools were harder and drier during oxycodone treatment (P<0.001) and 
colorectal volumes also increased (caecum/ascending colon by 41% (P=0.005) and 
transverse colon by 20% (P=0.005)) compared to placebo.  
- No association between questionnaire scores and colorectal volumes were detected. 
 
Interpretation: The oxycodone treatment regimen was sufficient to induce analgesia and experimental 
OIBD in healthy volunteers. The MRI-based method was sensitive to changes in colorectal volumes 
brought on by oxycodone treatment and the OIBD model itself shows potential for future 
interventional studies to discriminate efficacies of different laxative in combination with opioid 
treatments. 
 
4.3 Aim III 
Aim: To describe electrogenic epithelial ion transport in isolated mucosal biopsies from the 
rectosigmoid colon following five-day in vivo treatment with oxycodone compared to placebo and 
during in vitro addition of morphine (paper III). 
 
Key results: 
- No difference in basal SCC or basal G was found between any study days (all P > 0.05). 
- Addition of secretagogues (PGE2 and theophylline) produced similar baseline-corrected 
ΔSCC and ΔG during oxycodone and placebo treatments (P>0.05). 
- Addition of inhibitors (morphine and ouabain) produced similar baseline-corrected ΔSCC and 
ΔG during oxycodone and placebo treatments (P>0.05). In fact, morphine addition did not 
produce any response to ΔSCC and ΔG at all. 
 
Interpretation: In vivo oxycodone treatment in healthy volunteers does not alter electrogenic epithelial 
ion transport in the sigmoid colon. Neither does in vitro application of morphine to sigmoidal biopsies 
alter the electrogenic epithelial ion transport, evidently because of the absence of MORs in human 
colonic mucosa. As the secretory capacity and structural integrity appears intact in this segment 
despite oxycodone treatment it suggests that oxycodone treatment does not affect gut secretion in the 
distal colon. 
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4.4 Aim IV 
Aim: To evaluate how oxycodone treatment, compared to placebo, affects GI symptoms assessed by 
questionnaires and regional GI transit times using the 3D-Transit system (paper IV). 
 
Key results: 
- Gastrointestinal symptoms were present during oxycodone treatment compared to placebo 
treatment including constipation, straining or squeezing to pass stool, incomplete bowel 
movement, hard stools, abdominal pain, and bloating (all P<0.05). 
- Total GI transit and colorectal transit was significantly prolonged during oxycodone treatment 
(P<0.005) compared to placebo treatment. Within the colorectal segment, a post hoc analysis 
revealed increased transit time in the caecum/ascending colon (P=0.01) and the rectosigmoid 
colon (P=0.04).  
 
Interpretation: Experimental OIBD was evoked during oxycodone treatment according to 
questionnaire scores. Furthermore, objective information on transit times revealed the most 
pronounced delays occur in the caecum/ascending colon and the rectosigmoid colon. This model has 
great potential for future interventional studies to discriminate efficacies of different laxative and opioid 
treatments. 
 
4.5 Aim V 
The results from the sphincter function assessments have been investigated preliminarily but due to 
the complexity of these data a more elaborate data analysis is warranted. Nonetheless, the 
preliminary analysis reveals large variability, and no evidence of oxycodone-induced alterations in 
sphincter function and distensibility.  
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Chapter 5 Discussion 
In the present thesis a new experimentally induced model of OIBD in healthy volunteers was 
evaluated. The efficacy of the dosing regimen was validated through the development of analgesia to 
painful stimuli with muscle pressure algometry to the dorsal forearm. Furthermore, the induction of the 
most prevalent OIBD symptoms was determined by significant increases in all subjective bowel 
function questionnaires. Finally, objective quantification of four key aspects of OIBD was assessed 
with four novel methods and two of these detected clear changes in bowel function brought on by 
oxycodone treatment: MRI-based assessment of segmental colorectal volumes detected a clear 
increase in the proximal colon segments, while the 3D-Transit system found prolonged total GI transit 
time and within the colon; prolonged transit time in the caecum/ascending colon and rectosigmoid 
colon. On the other hand, no changes were detected in the electrogenic epithelial ion transport in 
isolated mucosal biopsies from the sigmoid colon and it has yet to be determined whether sphincter 
function and distensibility at rest and during challenge testing was affected by oxycodone treatment. 
The first part of this discussion contains methodological considerations regarding the use of MRI, 
Ussing chambers, and 3D-Transit to assess bowel function. The second part of the discussion 
revolves around the validity of the model itself and the feasibility of quantifying OIBD objectively with 
these modalities. 
5.1 Methodological considerations 
5.1.1 MRI 
Data obtained with MRI was used to compute segmental colorectal volumes at different time points. 
The scans provide a snapshot of the current colorectal filling, but do not provide any temporal 
information on for example GI motility. Because evaluation of colorectal volume with the Colometry 
segmentation software is based on manually placed regions of interests, this introduces an observer 
bias. To investigate this issue we have previously conducted an inter-observer study that showed 
negligible inter-observer bias in 14 MRI scans from four different HVs (Sandberg et al. 2015). Still, the 
colon is a highly dynamic organ and it is reasonable to expect large inter-individual and intra-
individual variation, e.g. as a consequence of variety in diet and exercise levels. Nevertheless, the 
results from study I indicate that the inter-individual variability is sufficiently low to gain meaningful 
information with this method, although a certain degree of standardisation is required. The results 
from Pritchard and colleagues who previously published a paper on the normal ranges of colorectal 
volumes in 75 HVs, support our findings (Pritchard et al. 2014). Still, it should be kept in mind that the 
homogenous population of healthy males in our study is not representative of the general population 
and in particular not of the often heterogeneous patient groups. Rather, the model should be viewed 
as a characterisation of gut physiology in a controlled environment to be used as a model in e.g. 
interventional studies exploring the efficacy of different drugs on OIBD. The feasibility is supported by 
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the semi-automatic method that reduces time expenditure and greatly improves applicability of the 
model and reduces the cost. The present application provides a quantitative snapshot with high 
spatial resolution of the colorectal volume distribution that is far superior to the quantification of 
constipation with standard abdominal x-ray, but it does not provide any temporal information in terms 
of e.g. gut motility or transit times. An increase in spatial resolution as well as information on transit 
can be gained by performing a series of contiguous scans at fixed time intervals or by combining the 
method with radio-opaque markers.  
 
5.1.2 Ussing chamber 
The current literature on gut secretion and opioids are mainly focused on Ussing chamber studies 
where chemical compounds with opioidergic agonistic/antagonistic properties are applied directly to 
mucosa specimens and no studies currently exist where the opioid exposure occurs in vivo. 
Accordingly, literature has been sparse to guide the present experiments. Nevertheless, the Ussing 
chamber was chosen due to its widespread applications and its previously proven aptitude in 
detecting opioid-mediated effects on gut secretion albeit in different settings (Kachur et al. 1980; 
Kromer 1995; Sun et al. 2011; Fei et al. 2010; Poonyachoti & Brown 1999; Poonyachoti & Brown 
2001). The majority of Ussing studies in human tissue rely on large tissue specimens from e.g. 
surgical resections (Brzuszczak et al. 1996; Archampong et al. 1972; Van De Kerkhof et al. 2006; 
Collins et al. 2011), which obviously is an option only during the presence of pathophysiological 
conditions such as colorectal carcinomas. For obvious reasons, a less invasive approach in HVs was 
required, which is the reason for the use of rectosigmoid mucosa biopsies. The method performed 
satisfactorily as the biopsies were both viable and responded to the added compounds as described 
in previous literature. However, intervention with oxycodone vs. placebo treatment did not show any 
appreciable difference. The reason is possibly that the biopsies were too superficial to include the 
enteric nervous system and that any effect on the enteric nervous system caused by opioid treatment 
was not present in the isolated mucosa. Assessment of opioid binding directly to the opioid receptors 
in the enteric nervous system, representing a “pure neurogenic effect” would obviously have been 
preferable, but this was not possible because of the risk of perforation during biopsy extraction. It can 
be argued that the electrogenic properties of only the mucosa do not reflect whether or not opioid 
treatment altered the colonic secretion.  
Evidence of opioid receptors being expressed on immune cells in the intestinal mucosa have been 
presented previously (Sternini et al. 2004). If in fact the rectosigmoid mucosal biopsies had contained 
such cells, we would have expected that the application of morphine in the Ussing chamber to bind to 
their opioid receptors and consequently alter the electrogenic properties. As this effect was not 
demonstrated, we do not believe that opioid receptor-presenting immune cells were present in the 
rectosigmoid mucosa.  
Another approach to obtain a quantifiable measure of altered gut secretion could be to measure 
stool water content using a freeze drying procedure (Hebden et al. 1999). Because stool water 
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content is also dependent on food and fluid intake, which varies greatly between individuals, this 
method would benefit from simultaneous collection of urine and either complete standardisation of 
food and fluid intake or more feasibly, precise monitoring of individual food and fluid intake. Other 
methods such as stool osmolality or electrolyte assays are conventionally used to determine the 
aetiology of diarrhoea (e.g. factitious diarrhoea, cholera toxin-induced diarrhoea (Steffer et al. 2012), 
and congenital chlorridorrhoea (Caspary 1986)) and may be of limited use in a constipation context as 
this method normally requires loose, watery faeces. 
 
5.1.3 3D-Transit system 
The 3D-Transit system provides a safe and minimally invasive ambulatory assessment of GI transit. 
The system was tolerated well by all subjects with only minor complaints on the system being 
uncomfortable during sleep or being slightly hot during the summertime. Capsule systems generally 
provide non-stationary recordings of gut motility and information on transit patterns rather than on 
site-specific motility patterns is provided. The 3D-Transit system has previously been validated 
against transit times obtained with radio-opaque markers with which it correlated well (Haase et al. 
2014). However, previous studies investigating the effect of opioids on GI motility and transit times 
have typically relied on scintigraphy and breath tests, which generally measure gastric emptying and 
small intestinal transit (Maurer et al. 1996; Yee et al. 1991; Thorén et al. 1989; Kaufman et al. 1988; 
Jeong et al. 2012; Prokop et al. 1988)). The ability of the 3D-Transit system to obtain whole gut and 
regional transit data under normal physiological conditions with or without an intervention is 
advantageous compared to these methods. Furthermore, because the 3D-Transit data is based on 
exact anatomical localisation accompanied by site-specific contraction frequencies it holds great 
potential because it enables study of not only transit times but also more detailed information of gut 
motility and contraction patterns (i.e. non-propulsive contractions vs. propulsive contractions and 
retrograde movement vs. anterograde movements). However, the interpretation of this dimension is 
complicated by movement artefacts introduced by postural changes and movement of the 3D-Transit 
detector. The detector has a built-in accelerometer that eventually will enable removal of these 
artefacts but for the time being further software development is required. 
Another limitation of this method in the present study design is the ingestion time of the 3D-transit 
capsule. The capsule was ingested immediately after the first dose of oral oxycodone along with a 
standardised meal. Because oral prolonged-release oxycodone is effective within 45 minutes with a 
peak plasma concentration within three hours and a half-life of approximately 4.5 hours it is highly 
unlikely that the oxycodone had time to take effect before the capsule was ingested. Therefore, it is 
not surprising that an oxycodone-induced difference in gastric emptying and small intestinal transit 
time was not found. On average, the capsule had traversed both stomach and small intestine within 8 
to 9 hours, at which point the oxycodone treatment may not yet have taken adequate effect in the 
ENS. For future application the window between first dose and capsule ingestion should be 
prolonged.  
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Concerning capsule expulsion, an interesting discovery was made by Wang et al. who investigated 
regional and whole gut transit times in 215 HVs (Wang et al. 2015). Here they found that the wireless 
motility capsule was often expelled with the first bowel movement of the day. This means that data for 
whole gut transit time is not normally distributed; rather it is clustered at values separated by 24 
hours. The same is likely true for the 3D-Transit capsule. However, because we measured altered GI 
function rather than normal GI function results may not be directly comparable. Not only did we 
change GI motility through oxycodone treatment, the ability of opioid treatment to decrease sensitivity 
to ‘fullness’ of the rectum which decreases the urge to defecate has previously been demonstrated 
(Musial et al. 1992). Therefore, we would not expect a normal bowel ‘rhythmicity’ in opioid-treated 
HVs. Furthermore, the main advantage of the 3D-Transit system compared to the wireless motility 
capsule is its capacity to determine the exact location in the GI tract of the capsule. This clustering of 
data in 24-hour intervals is associated only with capsule expulsion, meaning that when the capsule 
arrives in the rectum it will often be stored here until the next morning defecation. Again, this means 
that the discovery that transit is prolonged in the caecum/ascending colon will not have been affected 
by this phenomenon while the prolonged transit of the rectosigmoid colon may have been. 
 
5.2 Experimental OIBD model in healthy volunteers 
Regarding the model itself, clinical OIBD has been described in detail in the current literature, but to 
the best of the authors’ knowledge no experimental model in healthy volunteers currently exist 
(Pappagallo 2001; Brock et al. 2012). The applied oxycodone dose in the present study was given 
great consideration before initiating the study. On one hand it was imperative that the dose regimen 
was sufficiently high to produce as pronounced level of GI adverse effects as possible. On the other 
hand, and more importantly, there were ethical and safety concerns that required the dose regimen to 
be sufficiently low to not pose a risk for the HVs in terms of overdose, development of substance 
dependence, or withdrawal of consent because of intolerable adverse effects (expectedly those of the 
CNS such as sedation, dizziness, nausea). When the dose regimen was ultimately settled on 5 mg 
twice daily on day 1, 10 mg twice daily on day 2-4, and 10 mg once daily on day 5 it was based on 
previous experience with similar daily doses of opioids in HVs (Staahl et al. 2006; Olesen et al. 2010; 
Staahl et al. 2011; Brokjaer et al. 2015) and because this is a clinically relevant dose (albeit a rather 
low dose when discussing chronic pain disorders). Furthermore, when comparing the dose regimen 
with those of chronic pain, this experimental setup was also extremely short-term with only five days 
of treatment. Still, the present study population were healthy and opioid naïve so a cautionary 
approach was preferable. Despite these contrasts between the present experimental model of OIBD 
and true clinical OIBD, effects of oxycodone treatment was clearly demonstrated not only with 
subjective questionnaires, but supported by objective quantification with novel methods. The 
relevance of the applied dose regimen was substantiated with the demonstration of analgesia during 
pressure algometry. All of these factors combined are what makes up the ‘novel approach to assess 
OIBD’; a successful model in healthy volunteers that is highly unique and although the present study 
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population was highly homogenous it is feasible that the findings can be translated from ‘bench to 
bedside’ because the clinical manifestations of OIBD occur irrespective of age, gender, ethnicity. 
 
The model was capable of detecting oxycodone-induced alterations in both subjective and objective 
measures. However, no clear correlations between subjectively perceived symptoms and objective 
quantification of OIBD could be determined which is not unusual. For example, agreement between 
the patients’ own reports of GI function and objectively measured colonic transit time is modest 
(Chaussade et al. 1989; Ashraf et al. 1996). On the radiological side, assessments of colonic faecal 
loading with plain radiography and radio-opaque markers does not correlate with the subjective 
sensation of constipation (Grotz et al. 1994; Cowlam et al. 2008).  Even simple measures such as 
stool frequency and consistency may not be valid, as many opioid-treated patients report normal stool 
frequency, but experience symptoms of OIBD such as straining, bloating, and the feeling of 
incomplete bowel evacuation (Bell et al. 2009). Therefore, measures based on objective clinical 
assessment may not be valid for capturing the patient experience. Furthermore, there are several 
methodological parameters that could add to the absent correlations: First, as demonstrated with the 
PAC-SYM questionnaire in paper II, the onset of OIBD symptoms are gradual – on day 2 no 
difference in symptom score occurs, but on day 3 through day 5 the symptoms gradually increase and 
would likely have increased even further if treatment had not been stopped on day 5. This provides a 
partial explanation for the absent correlations between subjective and objective scores: OIBD 
gradually manifests and it is likely that subjective and objective scores will start to correlate with 
prolonged opioid exposure. As this is not feasible with healthy volunteers, the next obvious step is to 
apply these methods in actual chronic pain patients, who are in long-term opioid therapy, although the 
comorbidity, concomitant medication, reduced mobility and other confounding factors are introduced 
with these subjects. Alternatively, it might be possible to prolong opioid exposure in HVs with 
reductions in dose regimen and close monitoring of physical/psychological well-being. Another 
explanation for the absent correlations could be that while the objective measures are very well 
defined (e.g. volume and transit time), the subjectively perceived symptoms encompass a plethora of 
clinical manifestations (e.g. bloating, constipation, abdominal pain, xerostomia, etc.) and it varies 
greatly on an individual basis which symptom(s) will dominate the consciousness. Such 
heterogeneous clinical presentation will obviously counteract the detection of correlations but may 
become more uniform with prolonged exposure. Regarding the safety of the model, no alterations to 
subjects’ anxiety level occurred as a result of oxycodone treatment (paper IV). Similarly, no subjects 
showed evidence of substance dependence after oxycodone treatment had ceased (paper III). 
Therefore, this experimental model of OIBD appears to be well-tolerated and safe, which ensures its 
future application in investigating the underlying pathophysiology of OIBD in greater detail in a 
controlled environment free from the clinical confounders. Another possible application would be in 
studies investigating the efficacy of different opioids and laxative strategies, or the off-label efficacy of 
e.g. selective serotonin reuptake inhibitors to improve gut motility (Janssen et al. 2010). Currently, 
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assessment of laxative efficacy is based on SBMs and questionnaire-based assessments. Although 
these tools have proven efficient in the present study, we believe objective assessment provides 
important complementary information on the underlying mechanisms.  
  
5.2.1 MRI 
The objective MRI-based volumetric technique adds an interesting layer of information on top of the 
subjective questionnaire data. During oxycodone treatment a volume increase was found in the most 
oral colorectal segments (i.e. caecum/ascending colon and the transverse colon) while volume in the 
more anal segments remained relatively stable. Recent advances in detailing colonic motor patterns 
with high-resolution manometry may be key in understanding this proximal colonic volume increase 
during oxycodone treatment (Dinning et al. 2014). The same technique has been used to show that 
the normal increase in propagating motor patterns including high amplitude propagating sequences 
(mass movements) that occur after a meal is absent in patients with slow transit constipation (Dinning 
et al. 2015). The fact that opioids decrease gut motility coupled with the finding that high amplitude 
propagating sequences consistently originate in the proximal colon may provide a possible 
explanation for the volume accumulation we detect in the caecum/ascending colon and transverse 
colon if the high-amplitude propagating sequences are weakened due to treatment with oxycodone 
(Dinning et al. 2014). Conversely, the rectosigmoid volume remains relatively stable, which likely 
indicates that subjects were not experiencing opioid-induced evacuation disorders.  
A volume increase in the caecum/ascending colon volume was found during placebo treatment 
although this only accounted for a third of the difference observed during oxycodone treatment. In 
paper I the inter- and intra-individual variability of the caecum/ascending colon displayed the most 
pronounced level of variability between observations, which may provide a partial explanation 
(Nilsson et al. 2015). Another explanation could be the presence of a systematic bias in the study 
design, which causes an increase in caecum/ascending colon volume on day 5. Subjects were 
scanned at the same time of day but were only in a fasting state on day 1. As deftly shown by 
Pritchard and colleagues, an acute increase in ascending colon volume of 10-20% occurs 
postprandially, which tallies with the observed increase during placebo treatment of 14% and provides 
a possible explanation for this volume increase (Pritchard et al. 2014). However, because the 
magnitude of volume increase observed during oxycodone treatment far surpasses that of the 
placebo treatment and of the postprandial data, we consider that most of the volume increase is due 
to the local binding of oxycodone in the ENS. 
 
5.2.2 Ussing chamber 
It has previously been shown that the modified Ussing air-suction chamber allows assessing epithelial 
ion secretion of small tissue samples, which enables studies of healthy human volunteers (Larsen et 
al. 2001; Osbak et al. 2007). Biopsies remain viable for hours following extraction, and thus the 
 
61 
modified Ussing air-suction chamber method was chosen to assess basic and stimulated ion 
transport, to explore the underlying in vivo pathophysiological mechanisms of experimentally induced 
OIBD in healthy human volunteers. Therefore, a systemic five-day oxycodone exposure was expected 
to target opioid receptors within the enteric nervous system and cause a neurogenic decrease in 
secretion in the gastrointestinal tract. Furthermore, it was hypothesised that this neurogenic mediated 
effect on gut secretion would potentially induce long-term alterations in e.g. activation of epithelial 
chloride channels that would be present locally in the isolated mucosa biopsies. Conventional opioids 
(e.g. morphine and oxycodone) elicit high affinity towards the ORs. However, as MORs are not 
located in human gut mucosa but is found in the submucosal and myenteric ganglia and nerve fibres 
in the myenteric plexus (De Luca et al. 1996; Sternini et al. 2004), our biopsies may have been too 
superficial to include the ENS, and therefore were insufficient to assess the tissue effect following 
oxycodone treatment. As no observable changes in SCC was shown in response to five-day 
oxycodone treatment when compared to baseline, several methodological considerations should be 
addressed, in order to verify these negative findings. 
 
5.2.3 3D-Transit system 
The 3D-Transit system has not been approved for MRI and therefore capsule retention on day 5 
excluded MRI assessment. This caused the loss of MRI data in six subjects on day 5 during 
oxycodone treatment and in one subject on day 5 during placebo treatment. In itself, this highlights 
how effectively oxycodone treatment impacted normal gut function, but importantly, the six subjects 
that retained the 3D-Transit capsule on day 5 were per se also the six subjects with the longest transit 
time. Reasonably, these subjects were likely to also exhibit the most pronounced increase in 
colorectal volumes, which means that the MRI data are likely systematically underestimating the true 
increase in colorectal volumes following oxycodone treatment. Still, it is encouraging that the MRI and 
3D-Transit findings compliment each despite this underestimation; both methods detect an impact of 
oxycodone treatment in the caecum/ascending colon. However, the 3D-Transit system also detects 
prolonged transit time in the rectosigmoid colon whereas no difference is found in volume. This might 
be due to the unaltered passive absorption of the colon during opioid treatment; although faecal 
matter is accumulating in the rectosigmoid colon the water content is continuously being passively 
absorbed and hence, the volume remains relatively stable despite increasing density of the faecal 
matter. This hypothesis is substantiated by the increasing scores of drier and harder stools observed 
with the BSFS questionnaire (paper II).  
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Chapter 6 Conclusions and Future Studies 
 
In the presented new experimental model of OIBD, five-day treatment with oxycodone, compared to 
placebo, produces detectable alterations in GI function in healthy, opioid naïve males in terms of both 
subjective and objective aspects of gastrointestinal functions. No subjects withdrew their consent and 
no subject showed any evidence of increased anxiety or substance dependence as a result of the 
oxycodone treatment, which means that the study design is safe and well-tolerated.  
Assessments of MRI-based segmental colorectal volumes with the novel Colometry segmentation 
software exhibit low variability and the method is sensitive both to changes in volume brought on by 
defecation and changes resulting from oxycodone treatment. The opioid-induced increase in volume 
colonic volume corresponds to the observed delay in colonic transit time detected with the 3D-Transit 
system. On the other hand, gut secretion in isolated mucosa from the rectosigmoid colon does not 
appear to be altered due to opioid treatment. Also, the anal sphincter function and distensibility 
appear to be highly variable and is awaiting a more exhaustive data analysis.  
Ultimatel,y we successfully present a novel approach to assess OIBD in a controlled environment.  
 
With an experimental model of OIBD in HVs there are numerous evident targets for future studies. For 
example, with this model it is possible to assess the efficacy of e.g. naloxegol, tapentadol, or targin 
vs. conventional laxative treatment in the alleviation of OIBD. In fact, the next sub-study of the 
MULTIPAIN6-2013 protocol (sub-study 2a) is focused on comparing the effect of 1) oxycodone 
prolonged release in combination with naloxone prolonged release with 2) oxycodone and macrogol 
treatment in a double-blinded, randomized trial in 20 healthy volunteers. This sub-study utilises the 
same methodology as sub-study 1b, although the Ussing chamber studies have been omitted and the 
FLIP method refined in order to look specifically at the rectoanal inhibitory reflex.  
With this approach, the efficacy of different treatment strategies in terms of OIBD can be 
measured with not only self-assessed questionnaires and monitoring of SBMs but with objective, 
quantifiable measures as well. Using HVs in a controlled environment it is possible to gain insights 
into the pharmacological effect of study medication unmodified by comorbidity, concomitant 
pharmaceutical use, or pain-related psychosocial factors. Conclusions from such controlled settings 
are not necessarily representative of the actual patient population but the information will be no less 
important.  
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